Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s share price rose 11.3% during mid-day trading on Friday . The stock traded as high as $0.35 and last traded at $0.35. Approximately 100 shares traded hands during trading, a decline of 99% from the average session volume of 8,177 shares. The stock had previously closed at $0.3145.
Defence Therapeutics Stock Performance
The stock has a fifty day simple moving average of $0.35 and a 200-day simple moving average of $0.41.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
See Also
- Five stocks we like better than Defence Therapeutics
- Why Wall Street Suddenly Sees SpaceX as an AI Company
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
